Development of electrochemical genosensors for the detection of toxic dinoflagellate alexandrium spp.

Microalgae represent a photosynthetic microorganisms’ group that inhabit both salt and fresh waters. These microorganisms, namely several species of dinoflagellates (e.g. Alexandrium spp.)1 , are mostly harmless; however, some species produce toxins classified as unsafe to human health. The uncontrolled proliferation of such species results in a hazardous occurring event designated harmful algal blooms (HAB). The effects of these episodes can lead to severe ecological and socio-economic impacts (e.g. decrease of the local tourism, fishing and port activities, the contamination or death of the nearby wildlife, discoloration of the beach coasts). Therefore, the need for a rapid, selective and in real time detection device that can monitor the presence of these microalgae in aquaculture waters is critical to prevent human, ecological and economical losses. In this work, an analytical approach based on electrochemical genosensor techniques was developed to create a low cost platform able to detect the dinoflagellates: Alexandrium minutum and Alexandrium ostenfledii. The design of this genosensor consisted of several steps including: i) Sensing phase: Creation of a mixed self assembled monolayer (SAM) composed by a linear DNA capture probe (DNA-CP) and mercaptohexanol (MCH) onto screen-printed gold electrodes (SPGE) surface; ii) Heterogenous hybridization of complementary DNA sequence (DNA target) by using a sandwich format assay with enzymatic labels and iii) Electrochemical detection by chronoamperometry using an enzymatic scheme to amplify the electrochemical signal (Figure 1). The best analytical conditions were used to study the relationship between electrochemical signal and DNA target concentration.info:eu-repo/semantics/publishedVersio

Gellan-gum coated gold nanorods: a new tool for biomedical applications

Publicado em "Frontiers in Bioengineering and Biotechnology. Conference Abstract: 10th World Biomaterials Congress"Introduction: Gold nanorods (AuNRs) have been widely studied, in the scope of cancer research and biomedical applications [1]. Their optical properties, easy synthesis and high surface area make AuNRs an outstanding tool for a plethora of applications, such as drug delivery, imaging and tissue engineering [2]. However, before biomedical usage, it is necessary to modify AuNRs surface chemistry, to improve their biocompatibility and stability under biological conditions [3]. One possible approach is the use of biocompatible natural-based polymers that enhance AuNRs performance while allowing the controlled release of drugs/bioactive agents. Herein, we report the successful preparation of a core-shell nanostructure using low-acyl gellan gum (GG) [4], [5] for the coating of AuNRs. Methods: AuNRs were prepared following the seed-mediated growth method [6]. Then, particles were coated with a successive deposition of anionic and cationic polyelectrolytes (poly(acrylic acid) and poly(allylamine hydrochloride), respectively). The pre-coated nanorods were added to a low-acyl gellan gum (GG) solution, previously heated at 90ºC to allow dissolution, and the mixture was stirred overnight at room temperature. The GG-coated AuNRs (AuNR-GG) were characterized by UVvisible spectrometry, zeta potential measurements and transmission electron microscopy (TEM). AuNRs cytotoxicity was accessed in vitro after 1, 3, 7 and 14 days of SaOS-2 cell culture, using an MTS assay. Nanoparticles internalization was confirmed by TEM. In vivo biocompatibility tests were also performed by delivering a solution of AuNRs-GG via tail injection in mice. Results and Discussion: AuNRs were successfully synthesized and coated with a GG shell of approximately 7 nm, as shown in Figure 1. The presence of the GG around AuNRs clearly improved particles stability at different salt and pH conditions, as observed by UV-vis spectroscopy. The in vitro studies using SaOS-2 showed that AuNRs-GG are noncytotoxic. TEM analyses have confirmed that nanoparticles are uptaken by cells and aggregate within cytoplasmic vesicles as depicted in Figure 2. Additionally, in vivo tests suggest that AuNRs are harmless for mice after 24 hours. Conclusion: In this study, AuNRs were individually coated with a gellan gum (GG) shell, resulting in nanoparticles with enhanced stability under different salt concentrations and range of pH’s. Thence, one can conclude that the GG present around the nanoparticles acts as a stabilizer, improving AuNRs stability and biocompatibility. AuNRs-GG have shown noteworthy features and a high potential for further use on biomedical applications including intracellular drug delivery and imaging.QREN (ON.2 – NORTE-01-0124-FEDER-000018) co-financed by North Portugal Regional Operational Program (ON.2 – O Novo Norte), under the National Strategic Reference Framework (NSRF), through the European Regional Development Fund (ERDF)The Portuguese Foundation for Science and Technology (FCT) - SFRH/BD/102710/201

Chemically modified electrodes for the detection of antidepressants

Major depressive disorder is a widespread condition with antidepressants as the main pharmacological treatment. However, some patients experience concerning adverse reactions or have an inadequate response to treatment. Analytical chromatographic techniques, among other techniques, are valuable tools for investigating medication complications, including those associated with antidepressants. Nevertheless, there is a growing need to address the limitations associated with these techniques. In recent years, electrochemical (bio)sensors have garnered significant attention due to their lower cost, portability, and precision. Electrochemical (bio)sensors can be used for various applications related to depression, such as monitoring the levels of antidepressants in biological and in environmental samples. They can provide accurate and rapid results, which could facilitate personalized treatment and improve patient outcomes.info:eu-repo/semantics/publishedVersio

Electrochemical chemically based sensors and emerging enzymatic biosensors for antidepressant drug detection: a review

Major depressive disorder is a widespread condition with antidepressants as the main pharmacological treatment. However, some patients experience concerning adverse reactions or have an inadequate response to treatment. Analytical chromatographic techniques, among other techniques, are valuable tools for investigating medication complications, including those associated with antidepressants. Nevertheless, there is a growing need to address the limitations associated with these techniques. In recent years, electrochemical (bio)sensors have garnered significant attention due to their lower cost, portability, and precision. Electrochemical (bio)sensors can be used for various applications related to depression, such as monitoring the levels of antidepressants in biological and in environmental samples. They can provide accurate and rapid results, which could facilitate personalized treatment and improve patient outcomes. This state-of-the-art literature review aims to explore the latest advancements in the electrochemical detection of antidepressants. The review focuses on two types of electrochemical sensors: Chemically modified sensors and enzyme-based biosensors. The referred papers are carefully categorized according to their respective sensor type. The review examines the differences between the two sensing methods, highlights their unique features and limitations, and provides an in-depth analysis of each sensor.info:eu-repo/semantics/publishedVersio

Warfarin genetic biomarkers in VKORC1 and CYP2C9*2 genes: Advancing personalized anticoagulant therapy using electrochemical genosensors

The genetic variants of vitamin K epoxide reductase complex (VKORC1) and in the cytochrome CYP2C9*2 genes have been identified to influence the anticoagulant warfarin and influence its plasmatic levels. Therefore, the pharmacogenetic information on these genes is useful for reducing warfarin adverse reaction. This work addresses the development of disposable electrochemical genosensors able of detecting single nucleotide polymorphism (SNP) in the VKORC1 and CYP2C9*2 genes. The genosensor methodology implied the immobilization of a mixed self-assembled monolayer (SAM) linear DNA-capture probe and mercaptohexanol (MCH) onto screen-printed gold electrodes (SPGE). To improve the genosensor’s selectivity and avoid strong secondary structures, that could hinder the hybridization efficiency, a sandwich format of the DNA allele was designed using a complementary fluorescein isothiocyanate-labelled signaling DNA probe and enzymatic amplification of the electrochemical signal. The developed electrochemical genosensors were able to discriminate between the two synthetic target DNA targets in both SNPs, as well as the targeted denatured genomic DNA. Several analytical parameters, such as DNA capture probe, 6-mercaptohexanol (as spacer) and antibody concentrations, as well as hybridization temperature and incubation time, were optimized. Using the best analytical conditions calibration curves employing increasing DNA target concentractions were ploted. Polymerase Chain Reaction (PCR), will be used for further validation of the electrochemical genosensor. Disposable electrochemical genosensors capable of detecting and distinguishing between two synthetic CYP2C9*2 and VKORC1 polymorphic sequences, with high selectivity and sensibility and in various concentrations, was developed. The functionality of these analytical approaches as alternative to the conventional genotyping methodologies can relieve the public health-care systems and, hopefully, prevent ADRs related to CDV episodes.info:eu-repo/semantics/publishedVersio

Development of electrochemical genosensors for the CYPC*2 gene polymorphism detection

Pharmacogenetic studies search for heritable genetic polymorphisms that influence responses to drug therapy. Pharmacogenetics has many possible applications in cardiovascular pharmacotherapy including screening for polymorphisms to choose agents with the greatest potential for efficacy and least risk of toxicity. Pharmacogenetics also informs dose adaptations for specific drugs in patients with aberrant metabolism. Cardiovascular diseases (CVD) are considered one of the leading causes of death worldwide. To prevent cardiovascular complications and further loss of life oral anticoagulants (e.g., warfarin) are frequently prescribed to patients. Nevertheless, warfarin therapeutic agent presents narrow therapeutic windows with well-documented health risks. Some of these dose-responses are a result of specific single-nucleotide polymorphism (SNP) genetic variations present in a patient´s DNA. Among them, determined SNP in the cytochrome P4502C9 (CYP2C9), namely the CYP2C9*2, gene has been identified as dose-response altering SNP. Therefore, the need for a rapid, selective, low-cost and in real time detection device is crucial before prescribing any anticoagulant. In this work an analytical approach based on electrochemical genosensor technique is under development to create a low-cost genotyping platform able to genotype SNPs related with the therapeutic response of warfarin. Analyzing public databases, two specific 71 bp DNA probes, one with adenine (TA) and other with guanine (TG) SNP genetic variation were selected and designed. The design of this electrochemical genosensor consists of ssDNA immobilization onto gold surfaces that act as the SNPs complementary probes. The hybridization reaction is performed in a sandwich format of the complementary ssDNA, using an enzymatic scheme to amplify the electrochemical signal. The electrochemical signal was performed by using chronoamperometric technique.info:eu-repo/semantics/publishedVersio

VKORC1 gene polymorphism as cardiovascular biomarker: Detection by electrochemical genosensors

Warfarin is an anticoagulant generally used to prevent cardiovascular diseases. Since of the low therapeutic index of warfarin and frequent complications of prevention or treatment, significant differences in individual doses of warfarin are needed to achieve prophylactic and therapeutic ranges. Recent studies have been reporting that genetic variants of vitamin K epoxide reductase complex (VKORC1) influence the response to warfarin and doses [9]. So, the genetic and pharmacogenetic information of the major cardiovascular diseases plays an important role in the identification of the cardiovascular risk factors and in the diagnosis and treatment of these conditions. This work addresses the development of a disposable electrochemical genosensor able of detecting single nucleotide polymorphism (SNP) in the VKORC1 gene. Analysing public databases, two specific 52 bp DNA probes, one with adenine (TA) and another with guanine (TG) SNP genetic variation were selected and selected and designed. The genosensor methodology implied the immobilization of a mixed self-assembled monolayer (SAM) linear VKORC1 DNA-capture probe and mercaptohexanol (MCH) onto screen-printed gold electrodes (SPGE). To improve the genosensor´s selectivity and avoid strong secondary structures, that could hinder the hybridization efficiency, a sandwich format of the VKORC1 allele was designed using a complementary fluorescein isothiocyanate-labelled signaling DNA probe and enzymatic amplification of the electrochemical signal. Preliminary studies indicate that differences in the electrochemical answers were obtained depending of the hybridization reaction format. In fact, higher electrochemical intensities were measured when the hybridization reaction was performed with a complementary DNA (without SNPs). These results suggested that the sensor is able to discriminate between the complementary DNA and single base mismatch targets having a great potential for the DNA polymorphism analysis.info:eu-repo/semantics/publishedVersio

The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance.

Investment in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing in Africa over the past year has led to a major increase in the number of sequences that have been generated and used to track the pandemic on the continent, a number that now exceeds 100,000 genomes. Our results show an increase in the number of African countries that are able to sequence domestically and highlight that local sequencing enables faster turnaround times and more-regular routine surveillance. Despite limitations of low testing proportions, findings from this genomic surveillance study underscore the heterogeneous nature of the pandemic and illuminate the distinct dispersal dynamics of variants of concern-particularly Alpha, Beta, Delta, and Omicron-on the continent. Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve while the continent faces many emerging and reemerging infectious disease threats. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century

The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance

INTRODUCTION Investment in Africa over the past year with regard to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing has led to a massive increase in the number of sequences, which, to date, exceeds 100,000 sequences generated to track the pandemic on the continent. These sequences have profoundly affected how public health officials in Africa have navigated the COVID-19 pandemic. RATIONALE We demonstrate how the first 100,000 SARS-CoV-2 sequences from Africa have helped monitor the epidemic on the continent, how genomic surveillance expanded over the course of the pandemic, and how we adapted our sequencing methods to deal with an evolving virus. Finally, we also examine how viral lineages have spread across the continent in a phylogeographic framework to gain insights into the underlying temporal and spatial transmission dynamics for several variants of concern (VOCs). RESULTS Our results indicate that the number of countries in Africa that can sequence the virus within their own borders is growing and that this is coupled with a shorter turnaround time from the time of sampling to sequence submission. Ongoing evolution necessitated the continual updating of primer sets, and, as a result, eight primer sets were designed in tandem with viral evolution and used to ensure effective sequencing of the virus. The pandemic unfolded through multiple waves of infection that were each driven by distinct genetic lineages, with B.1-like ancestral strains associated with the first pandemic wave of infections in 2020. Successive waves on the continent were fueled by different VOCs, with Alpha and Beta cocirculating in distinct spatial patterns during the second wave and Delta and Omicron affecting the whole continent during the third and fourth waves, respectively. Phylogeographic reconstruction points toward distinct differences in viral importation and exportation patterns associated with the Alpha, Beta, Delta, and Omicron variants and subvariants, when considering both Africa versus the rest of the world and viral dissemination within the continent. Our epidemiological and phylogenetic inferences therefore underscore the heterogeneous nature of the pandemic on the continent and highlight key insights and challenges, for instance, recognizing the limitations of low testing proportions. We also highlight the early warning capacity that genomic surveillance in Africa has had for the rest of the world with the detection of new lineages and variants, the most recent being the characterization of various Omicron subvariants. CONCLUSION Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve. This is important not only to help combat SARS-CoV-2 on the continent but also because it can be used as a platform to help address the many emerging and reemerging infectious disease threats in Africa. In particular, capacity building for local sequencing within countries or within the continent should be prioritized because this is generally associated with shorter turnaround times, providing the most benefit to local public health authorities tasked with pandemic response and mitigation and allowing for the fastest reaction to localized outbreaks. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century